Clinerion welcomes the Santa Casa da Misericordia hospital to the Patient Network Explorer hospital network

Wednesday, December 5, 2018 @ 1:30 pm

The Santa Casa da Misericordia hospital of Porto Alegre, Brazil, will expand Clinerion’s network of partner hospitals in Brazil. Patients from the hospital’s seven clinics will gain access to leading-edge, innovative medical treatment via Clinerion’s Patient Network Explorer platform.

On the Patient Network Explorer, patients of Santa Casa da Misericordia will have the opportunity to be matched to international clinical trials being run by pharmaceutical companies and clinical investigators around the world. Participation in these trials enhances their access to leading-edge, innovative medical treatments and care. Users of Patient Network Explorer will gain an expanded insight into the patient population in Brazil and be able to make strategic drug development decisions based on real-time, real-world data.

“Together with our partner, iHealth, Clinerion is in the process of a significant push to encompass coverage of the majority of patients in Brazil,” says Clinerion CEO Ian Rentsch. “Santa Casa da Misericordia represents an important addition to Clinerion’s network of partner hospitals in the country, the region, and the world.” "Santa Casa has a long tradition in Clinical Research and the Clinerion / iHealth Patient Network Explore will help us maintain leadership in this area,” says Dr. Jorge Hetzel, Medical Director for Teaching and Research.

You may also be interested in

Swiss Biotech Report 2024 shows sector performing well in 2023 by continuing to embrace international alliances

Record revenues of CHF 7.3 billion (USD 8.1 billion) – Capital investments increase by more than 50% to CHF 2 billion – CHF 1.4 billion by public companies, CHF 0.6 billion by private companies – Significant licensing and M&A activity in 2023 – VectivBio, T3, Vertex, Santhera – R&D investments of publicly traded biotech companies have decreased in line with global markets, wherea
April 23, 2024

SOTIO enters into agreement with Biocytogen to expand antibody-drug conjugates pipeline

Option and license agreement includes multiple fully human bispecific antibodies generated with Biocytogen’s proprietary RenLite platform Agreement will enable SOTIO to significantly broaden its next-generation ADC portfolio, including multi-specific ADCs Biocytogen will receive an upfront payment and potential development milestone payments totaling up to $325.5 million
July 16, 2024

Asceneuron secures USD 100 million financing to advance therapeutics in neurodegenerative diseases

Financing led by Novo Holdings, including new investment from EQT Life Sciences – LSP Dementia Fund, OrbiMed and SR One with participation from existing investors M Ventures, Sofinnova Partners, GSK Equities Investments Limited and Johnson & Johnson Innovation – JJDC, Inc. Funds will be used to progress lead asset ASN51, an oral small molecule OGA inhibitor, into Phase 2 clinical developme
July 16, 2024

LimmaTech appoints Staph Leavenworth Bakali as Chairman of the Board

LimmaTech Biologics AG, a clinical-stage biotech company developing vaccines for the prevention of life-threatening diseases, today announced the appointment of Staph Leavenworth Bakali as independent Chairman of its Board of Directors. Mr. Leavenworth Bakali brings over 30 years of senior executive and board-level experience in the life science and healthcare industries.
July 1, 2024

Newron flash update “A pivotal year” - potential of schizophrenia drug

June 27, 2024

Ymmunobio and EVIIVE: Collaboration to develop advanced liquid biopsy for cancer patients

Ymmunobio and EVIIVE are pleased to announce their strategic collaboration to develop an innovative liquid biopsy technology utilizing extracellular vesicles (EVs). This partnership marks a significant advancement in precision medicine, aiming to enhance disease detection and patient monitoring accuracy and efficacy.
June 24, 2024